Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Anagrelide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B known ✓ | Q13370 | 19/20 | 0.71 |
| ▸ | PDE3A known ✓ | Q14432 | 19/20 | 0.71 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | PDE2A | O00408 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HBB | P68871 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anagrelide SCHEMBL29491059 | 0.84 | PDE3B (1.00) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL5060881 | 0.84 | PDE3B (1.00) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL9411 | 0.84 | PDE3B (1.00) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL318593 | 0.83 | PDE3B (0.97) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL9046734 | 0.83 | PDE3B (0.97) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL1449704 | 0.83 | PDE3B (0.97) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL1568712 | 0.83 | PDE3B (0.97) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL729172 | 0.82 | PDE3B (0.94) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL16335881 | 0.79 | PDE3B (0.87) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL1664162 | 0.78 | PDE3B (0.85) | PDE3BPDE3AP2RY12MEN1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210252004-A1 | USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | WEX MEDICAL LIMITED (HK) | 2021-08-19 | — | — | US | disclosed |
| EP-2274010-A1 | THERAPEUTIC COMBINATIONS OF ANTI-IGF-1R ANTIBODIES AND OTHER COMPOUNDS | Biogen Idec MA Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009126304-A1 | THERAPEUTIC COMBINATIONS OF ANTI-IGF-1R ANTIBODIES AND OTHER COMPOUNDS | BIOGEN IDEC MA INC. (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252004-A1 | USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | SCN10A, SCN5A, SCN3A | PDE3B 1289/4885PDE3A 1101/4885P2RY12 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.